14 results
424B3
EVOK
Evoke Pharma Inc
14 Mar 24
Prospectus supplement
6:44pm
or equal to [***] of API is damaged, lost or otherwise rendered unusable at any one time as soon as practicable following such incident. In addition
8-K
EX-1.1
EVOK
Evoke Pharma Inc
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited … , not misleading.
4.6 Corporate Proceedings. All corporate proceedings and other legal matters incident to the authorization, form and validity of each
8-K
EX-1.1
x7l2ze24waakpsk7d
14 Jan 21
Evoke Pharma Announces Proposed Public Offering of Common Stock
5:22pm
424B5
k02scybw xnqp
22 Jul 16
Prospectus supplement for primary offering
12:00am
8-K
EX-10.1
9ym0w3f07922a8fkkb
20 Jul 16
Evoke Pharma Announces $4.5 Million At-The-Market Offering
12:00am
424B5
kfb5h6e
20 Jul 16
Prospectus supplement for primary offering
12:00am
8-K
EX-3.2
al1vzpwof103vcqn8n
30 Sep 13
Amendments to Articles of Incorporation or Bylaws
12:00am
424B4
95e 6r9krzqcyygg
25 Sep 13
Prospectus supplement with pricing info
12:00am
- Prev
- 1
- Next